Genmab — Juni 2016
-
Dr. Jesus San Miguel noted that when POLLUX data mature, the median progression free survival (PFS) will likely reach a whopping 40 months or more than 3 years.
-
Endnu bedre
-
It could even be median PFS of 50 months
-
De foregående quotes er fra Novod der igår har deltaget I et pre EHA symposium
-
Mere fra JNJs Caruso: and I think also the way we responsibly price cancer therapy is important. We are very careful....
-
Dara's tal er så imponerende, at 1st Line efterhånden ligner unmet need...
-
We came to the pricing strategy in conjunction with oncology experts in the field
-
Enig Nohope.
-
Forretningsmodellen duer ikke kommercielt.
-
derfor er der vel stadig mange brugere her, der kan kunne give en skilling til forbedringer etc. Vi er da rigtig mange,,der bruger mange timer her om dagen, og vel og mærke rigtig mange, der har investeret tonsvis af penge! Jeg er med på at donere, helt uden tvivl kan reklamer ikke holde det kørende!
-
Fra Danske her til morgen: GENMAB: Darzalex/daratumumab ph3 POLLUX data expected 16:50cet. Key data known
but additional data could be positive even if expectations are high.
Jeg sidder klar. Er helt enig med mobbyHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind